Peer-reviewedCC BYAnnals of medicine and surgery (2012)
Advances in pharmacologic management of obesity: oral semaglutide for weight management
- 1Department of Medicine, King Edward Medical University, Lahore, Pakistan
Related
- CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis
- Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study
- Linafexor, a Pulsatile FXR Agonist, Augments Low-Dose Semaglutide for Weight Loss in Adults with Obesity, MASH, and Type 2 Diabetes
- Post-Initiation Care Patterns and Weight Loss With Semaglutide and Tirzepatide for Obesity in Clinical Practice
- Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders
BibTeX
@article{zainab2026advances,
title = {{Advances in pharmacologic management of obesity: oral semaglutide for weight management}},
author = {Fnu Zainab and Abdul Haseeb Hasan},
journal = {Annals of medicine and surgery (2012)},
year = {2026},
month = sep,
url = {https://europepmc.org/article/PMC/PMC13657554},
note = {CC BY},
}
RIS
TY - JOUR
TI - Advances in pharmacologic management of obesity: oral semaglutide for weight management
AU - Fnu Zainab
AU - Abdul Haseeb Hasan
PY - 2026
DA - 2026/09/08
JO - Annals of medicine and surgery (2012)
UR - https://europepmc.org/article/PMC/PMC13657554
SN - 2049-0801
ER -